Immunai

Immunai is a company based in New York, United States, that works on decoding the immune system. It partners with top biopharmaceutical companies and research institutions to discover and advance novel therapeutics. Its platform helps pharma companies make smarter choices, reduce risks, and accelerate progress through three key solutions: Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization. The company collaborates with AstraZeneca and Teva in drug discovery and development.

Immunai is a company in New York, United States. It partners with top biopharmaceutical companies and research institutions to discover and advance novel therapeutics. Its collaborations include partnerships with AstraZeneca for IBD target discovery and with Teva for vitiligo disease mechanism and biomarker discovery for Teva's IL15 targeted antibody.

Immunai positions its platform as helping pharma companies make smarter choices, reduce risks, and accelerate progress.

• 2021.10.28

  Reported2021.10.28

  Immunai raises $215 million in Series B funding[2]Immunai 完成 2.15 亿美元 B 轮融资pharmaceutical-business-review.com

  Immunai raised $215 million in a Series B funding round led by Koch Disruptive Technologies. The article says the company planned to use the funds to expand its drug actuary platform.

Read more

1. 1Immunai - Decoding immunityimmunai.com
2. 2Immunai 完成 2.15 亿美元 B 轮融资pharmaceutical-business-review.com